Europe Infectious Disease Therapeutics Market
No. of Pages: 106 | Report Code: BMIRE00030411 | Category: Life Sciences
No. of Pages: 106 | Report Code: BMIRE00030411 | Category: Life Sciences
The Europe infectious disease therapeutics market was valued at US$ 35,451.86 million in 2022 and is expected to reach US$ 49,108.21 million by 2030; it is estimated to register a CAGR of 4.2% from 2022 to 2030.Increasing Focus on Funding and R&D in Infectious Disease Therapeutics Drives Europe Infectious Disease Therapeutics Market
Research and development (R&D) is a critical part of the business of biopharmaceuticals and pharmaceutical companies. R&D enables them to launch new products for several therapeutic applications with significant medical and commercial potential. Also, leading market players are investing in R&D to develop enhanced technologies and gain more revenue share.
In order to create solutions for the most important health issues that Europe and the rest of the world are currently encountering, the European Union is investing in research, technology, and innovation. The European Commission has led the way in promoting research, particularly that related to immunity to and management of infectious diseases. Between 2007 and 2019, more than US$ 4.3 billion (4 billion) was allocated to the study of infectious diseases. Further, Horizon Europe, the upcoming (2021-2027) EU funding initiative for research and innovation (R&I), will carry on supporting R&I for infectious diseases, notably those associated with poverty, those that are neglected, and those that are (re-)emerging.
Horizon Europe is a program dedicated to supporting research and innovation. To bridge barriers across regions and establish tangible collaborations, the program places a strong emphasis on ensuring cooperation between universities, scientific communities, industry, especially small and medium-sized firms, and individuals. The Health Work Programme outlines funding options under Horizon Europe for research related to infectious diseases and pandemic preparedness and response. Thus, rising focus on R&D and funding in infectious disease therapeutics drive the infectious disease therapeutics market growth.Europe Infectious Disease Therapeutics Market Overview
The Europe infectious disease therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global infectious disease therapeutics market and is estimated to register a notable CAGR during 2022-2030. The region has an increased incidence of chronic viral diseases and a high demand for developing new anti-viral drugs. With US$ 15.79 billion funded from 2007 to 2019 through the 7th Framework Program and Horizon 2020 and the US$ 1.1 billion pledged for COVID-19 research, Europe plays a crucial role in funding and coordinating research on infectious diseases. According to The Robert Koch Institute, in Germany, ~400,000 to 600,000 patients suffer a hospital-acquired infection each year, among which 10,000-15,000 die. Typical problems for healthcare providers are surgical site infections, urinary tract infections, and pneumonia. The demand for anti-infective agents in Germany is growing significantly, attributed to the rising geriatric population, the increasing prevalence of chronic viral diseases, and the growing demand to produce new molecules for viral therapeutic areas to fulfill unmet conditions. Germany is one of the leading nations for anti-viral agent manufacturing and growth potential in Europe due to the high quality of its finished products. For instance, Atriva Therapeutics GmbH, a biopharmaceutical company, developed ATR-002 to treat patients with COVID-19 in a Phase II Study to block viral propagation of SARS-CoV-2. Therefore, due to the abovementioned factors, the market is expected to grow significantly in the country.
Europe Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
Strategic insights for the Europe Infectious Disease Therapeutics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the Europe Infectious Disease Therapeutics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
Get more information on this report Europe Infectious Disease Therapeutics Strategic Insights
Get more information on this report Europe Infectious Disease Therapeutics Report Scope
Report Attribute
Details
Market size in 2022
US$ 35,451.86 Million
Market Size by 2030
US$ 49,108.21 Million
Global CAGR (2022 - 2030)
4.2%
Historical Data
2020-2021
Forecast period
2023-2030
Segments Covered
By Drug Class
By Indication
By Distribution Channel
Regions and Countries Covered
Europe
Market leaders and key company profiles
Get more information on this report Europe Infectious Disease Therapeutics Regional Insights
Get more information on this report
Europe Infectious Disease Therapeutics Market Segmentation
The Europe infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.
Based on drug class, the Europe infectious disease therapeutics market is segmented into anti-viral, anti bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.
In terms of indication, the Europe infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.
Based on route of administration, the Europe infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.
In terms of distribution channel, the Europe infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.
By country, the Europe infectious disease therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe infectious disease therapeutics market share in 2022.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the Europe infectious disease therapeutics market.
1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. BioCryst Pharmaceuticals Inc
5. F. Hoffmann-La Roche Ltd
6. Gilead Sciences Inc
7. GSK Plc
8. Merck & Co Inc
9. Pfizer Inc
10. Shionogi & Co Ltd
The Europe Infectious Disease Therapeutics Market is valued at US$ 35,451.86 Million in 2022, it is projected to reach US$ 49,108.21 Million by 2030.
As per our report Europe Infectious Disease Therapeutics Market, the market size is valued at US$ 35,451.86 Million in 2022, projecting it to reach US$ 49,108.21 Million by 2030. This translates to a CAGR of approximately 4.2% during the forecast period.
The Europe Infectious Disease Therapeutics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Infectious Disease Therapeutics Market report:
The Europe Infectious Disease Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Infectious Disease Therapeutics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Infectious Disease Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Infectious Disease Therapeutics Market
